Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 56
- Registration Number
- NCT02070692
- Locations
- 🇺🇸
Oregon Health & Science University (OHSU), Portland, Oregon, United States
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2022-04-27
- Target Recruit Count
- 688
- Registration Number
- NCT02062489
- Locations
- 🇨🇳
Guangdong Women and Children Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 115
- Registration Number
- NCT01896050
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2020-03-04
- Target Recruit Count
- 412
- Registration Number
- NCT01758146
- Locations
- 🇮🇳
Department of Radiotherapy, Post Graduate Institute of Medical Education & Research, Chandigarh, India
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT01685255
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 56
- Registration Number
- NCT01638247
- Locations
- 🇩🇪
Kliniken Essen-Mitte, Essen, Nordrhein-Westfalen, Germany
Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 52
- Registration Number
- NCT01614210
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 1884
- Registration Number
- NCT01579734
- Locations
- 🇮🇹
European Institute of Oncology, Milan, Italy
A Study of LY2228820 in Participants With Advanced Cancer
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 89
- Registration Number
- NCT01393990
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.